TCGA-98-8020-01A-11R-2247-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- MYC_TARGETS_V2+0.540
- WNT_BETA_CATENIN_SIGNALING+0.470
- TGF_BETA_SIGNALING+0.460
- TNFA_SIGNALING_VIA_NFKB+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.420
- ANGIOGENESIS+0.400
- G2M_CHECKPOINT+0.370
- MITOTIC_SPINDLE+0.370
- APICAL_JUNCTION+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.260
- BILE_ACID_METABOLISM-0.230
- FATTY_ACID_METABOLISM-0.180
- KRAS_SIGNALING_DN-0.150
- SPERMATOGENESIS-0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.140
- XENOBIOTIC_METABOLISM-0.090
- PEROXISOME-0.070
- ADIPOGENESIS-0.030
- PANCREAS_BETA_CELLS+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.931 |
| 2 | SRR934760 | — | — | 0.902 |
| 3 | SRR934962 | — | — | 0.894 |
| 4 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.892 |
| 5 | SRR10900575 | — | — | 0.892 |
| 6 | SRR934963 | — | — | 0.886 |
| 7 | F547C7BB-DBF1-4805-A0EA-D8BC36606032 | — | — | 0.885 |
| 8 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.881 |
| 9 | TCGA-FD-A6TK-01A-42R-A33J-07 | — | — | 0.877 |
| 10 | MDT-AP-0435 | Med | Medulloblastoma | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |